About the AG

  • Subscribe to the AG's RSS Feed
  • Join the AG's FaceBook
  • Follow the AG on Twitter
  • View the AG's YouTube Channel
  • View the AG's Tumblr Page


Any planned research project to be conducted in California requiring the use of a Schedule I or Schedule II Controlled Substance (NOT Schedule III, IV, and V) as its main study drug, including comparing drug, must be submitted to the Research Advisory Panel of California for review and approval.

  • Researches are categorized into 4 groups:

    • Group 1: Academic Human Research of Schedule I or Schedule II medications
    • Group 2: Research for the Treatment of Controlled Substance Addiction or Abuse utilizing ANY

      medications (scheduled & non-scheduled) by Academic Institution (SAT Research)

    • Group 3: Non-Human Research with animal models OR in-vitro projects of Schedule I medications only

    • Group 4: Multi or Single Center Clinical Drug Trial Research sponsored by Pharmaceutical company/CRO

      evaluating or comparing any Schedule I and II medications AND Multi or Single Center SAT Research

  • Submission Requirements for each group:
    1. Group 1 and Group 2 - See Application Forms:
      1. Cover letter
      2. Panel Application Form
      3. Research Protocol, Not a Grant Application
      4. Informed Consent Form with Filled-out Informed Consent Form Check List
      5. Study Drug Monographs or Investigators Brochure
    2. Group 3: Requirements are same as group I and group 2 EXCEPT Informed Consent Form not required - See Application Forms

    3. Group 4 - See Clinical Drug Trials:
      1. Cover letter
      2. Research Protocol
      3. Template Informed Consent Form with Filled-out Informed Consent Form Check List
      4. Investigators Brochure
      5. List of each CA site's address and Principle Investigator (PI)'s name and e-mail address (No CV required)
  • For Group 4 researches, Research Advisory Panel grants the approval to the Sponsor, not the individual MD's or sites participating in the study. Therefore, the Pharmaceutical company/CRO is required to submit the study applications to the Panel, not the individual MD's or sites participating in the study.

  • Non-Human researches using Schedule II Substances or Any Researches using Schedule III, IV, or V Controlled Substances as a main study drug including comparing drug do NOT require review by the Research Advisory Panel.

  • The IRB approval status of all the research studies could either be approved or pending. In order to expedite the Panel's approval process, the researchers can submit their studies while the IRB approval is pending.

  • The response of the Panel review will be delivered via PDF format within 7 days after the meeting.

  • Any significant study drug related Serious Adverse Event (SAE) that may emerge during conduction of the research (at the California sites only) should be notified to the Panel via PDF format only.

  • Any amendments of the research project should be reported to the Panel via PDF format only. If the Panel considers that there are major amendments involved, the Panel reviews them at its regular scheduled meetings. Otherwise, the Panel acknowledges, files the amendments and send out an acknowledge letter via PDF format.
  • When the research study is completed, notify the RAPC in a letter form including a study completion date, and a final summary report of the study, and a drug usage log sheet if applicable in a PDF format only.

Megan's Law

California Registered Sex Offender Database

Search Now

Megan's Law information is also available in these languages:

Site Navigation

Translate Website

  • Google™ Translation Disclaimer

This Google™ translation feature is provided for informational purposes only.

The Office of the Attorney General is unable to guarantee the accuracy of this translation and is therefore not liable for any inaccurate information resulting from the translation application tool.

Please consult with a translator for accuracy if you are relying on the translation or are using this site for official business.

If you have any questions please contact:Bilingual Services Program at (916) 324-5482

A copy of this disclaimer can also be found on our Disclaimer page.

Select a Language Below / Seleccione el Idioma Abajo

Close this box or use the [ X ]